The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases

Biomaterials

Volumn 30, Issue 10, 2009, Pages 1890-1897

  Skarja, Gary A ^a   Brown, Allison L ^a   Ho, Rebecca K ^a   May, Michael H ^a   Sefton, Michael V ^a  

^a Rimon Therapeutics Ltd   (Canada)

Author keywords

Copolymer; Hydroxamic acid; Matrix metalloproteinase; Microsphere

Indexed keywords

ACTIVE MATRIXES; BINDING AFFINITIES; BINDING CAPACITIES; BINDING INTERACTIONS; CATALYTIC SITES; CHRONIC WOUND FLUIDS; COMPETITIVE ADSORPTIONS; CONCENTRATION DEPENDENTS; COPOLYMER; DERIVATIZATION OF; DIRECT INTERACTIONS; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; METHACRYLIC ACIDS; METHYL METHACRYLATES; MICROSPHERE; MMP ACTIVITIES; MMP INHIBITORS; MULTI COMPONENTS; POLYMER MICROSPHERES; POST POLYMERIZATIONS; PREFERENTIAL BINDINGS; ZINC ATOMS;

ACIDS; ACRYLIC MONOMERS; ADSORPTION; BINDING ENERGY; BLOOD VESSELS; CHEMICAL REACTIONS; COPOLYMERIZATION; ENZYME INHIBITION; ESTERS; MICROSPHERES; ORGANIC ACIDS; ORGANIC POLYMERS; POLYACRYLATES; POLYMERS; ZINC;

ULSI CIRCUITS;

COLLAGENASE 3; GELATINASE A; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MICROSPHERE; NEUTROPHIL COLLAGENASE; POLY(METHYL METHACRYLATE); POLYMER; STROMELYSIN; ZINC;

ADSORPTION; ADSORPTION KINETICS; ARTICLE; ATOM; BINDING AFFINITY; BINDING SITE; CATALYSIS; CONCENTRATION RESPONSE; DERIVATIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; EXTRACT; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; WOUND FLUID;

BIOCOMPATIBLE MATERIALS; ENZYME ACTIVATION; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MICROSPHERES; POLYMERS;

EID: 59649110262     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.12.040     Document Type: Article

References (38)

1. Chang Y.H., Lin I.L., Tsay G.J., Yang S.C., Yang T.P., Ho K.T., et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 41 12 (2008) 955-959
2. Davidson R.K., Waters J.G., Kevorkian L., Darrah C., Cooper A., Donell S.T., et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther 8 4 (2006) R124-R135
3. McGowan P.M., and Duffy M.J. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 19 9 (2008) 1566-1572
4. Hannas A.R., Pereira J.M., Granjeiro J.M., and Tjaderhane L. The role of matrix metalloproteinases in the oral environment. Acta Odontol Scand 65 1 (2007) 1-13
5. Demedts I.K., Morel-Montero A., Lebecque S., Pacheco Y., Cataldo D., Joos G.F., et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 61 3 (2006) 196-201
6. von Lampe B., Barthel B., Coupland S.E., Reicken E.O., and Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47 1 (2000) 63-73
7. Carrell T.W., Burnand K.G., Wells G.M., Clements J.M., and Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 105 4 (2002) 477-482
8. Subramaniam K., Pech C.M., Stacey M.C., and Wallace H.J. Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer fluid. Int Wound J 5 1 (2008) 79-86
9. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 87 14 (1990) 5578-5582
10. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 1-2 (2003) 269-285
11. Knauper V., Wilhelm S.M., Seperack P.K., DeClerck Y.A., Langley K.E., Osthues A., et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 295 Pt 2 (1993) 581-586
12. Balbin M., Fueyo A., Knauper V., Penda A.M., Lopez J.M., Jimenez M.G., et al. Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes: analysis of its potential role in postpartum involution of the uterus. J Biol Chem 273 37 (1998) 23959-23968
13. Knauper V., Murphy G., and Tschesche H. Activation of human neutrophil procollagenase by stromelysin 2. Eur J Biochem 235 1-2 (1996) 187-191
14. Holopainen J.M., Moilanen J.A., Sorsa T., Kivela-Rajamaki M., Tervahartiala T., Vesaluoma M.H., et al. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci 44 6 (2003) 2550-2556
15. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11 (2006) 1696-1701
16. Peterson J.T. Matrix metalloproteinase inhibitor development and the remodelling of drug discovery. Heart Fail Rev 9 1 (2004) 63-79
17. Murphy G., and Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 29 5 (2008) 290-308
18. Konstantinopoulos P.A., Karamouzis M.V., Papatsoris A.G., and Papavassiliou A.G. Matrix metalloproteinase inhibitors as anticancer agents. Mol Aspects Med 29 5 (2008) 1156-1168
19. Eckhaus A.A., Fish J.S., Skarja G.A., Semple J.L., and Sefton M.V. Poly(methacrylic acid-co-methyl methacrylate) beads enhance angiogenesis and improve survival of the Panniculus Carnosus in rodent skin grafts. Plast Reconstr Surg 122 5 (2008) 1361-1370
20. Sibbald RG, Coutts P, Woo K, Coehlo S, Ho RK, Skarja, GA. Random controlled trial of matrix metalloprotease inhibiting dressing with foam dressing compared to a foam dressing alone for the measurement of metalloproteases and the healing of stalled chronic wounds, in preparation.
21. Koklitis P.A., Murphy G., Sutton C., and Angal S. Purification of recombinant human prostromelysin: studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities. Biochem J 276 Pt 1 (1991) 217-221
22. Suzuki K., Enghild J.J., Morodomi T., Salvesen G., and Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 29 44 (1990) 10261-10270
23. Nwomeh B.C., Liang H.X., Cohen I.K., and Yager D.R. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res 81 2 (1999) 189-195
24. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69 3 (2006) 677-687
25. Vernon F., and Eccles H. Chelating ion-exchangers containing N-substituted hydroxylamine functional groups, Part IV. Column separations on a hydroxamic acid resin. Anal Chim Acta 83 (1976) 187-193
26. Vernon F., and Zin W. Chelating ion exchangers containing N-substituted hydroxylamine functional groups, Part 6. Sorption and separation of gold and silver by a polyhydroxamic acid. Anal Chim Acta 123 (1981) 309-313
27. Kamble K.J., and Patkar D.N. Synthesis and characterization of hydroxamic acid resin of poly(4-vinyl-2-carboxybenzophenone). J Appl Polym Sci 52 10 (1994) 1361-1364
28. Winston A., Varaprasad P., Metterville J., and Rosenkrantz H. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload. J Pharmacol Exp Ther 232 3 (1985) 644-649
29. Gehlbach P.L., Purple R.L., Hallaway P.E., and Hedlund B.E. Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. Invest Ophthalmol Vis Sci 34 10 (1993) 2871-2877
30. Domb AJ, Langer RS, Cravalho EG, Golomb G, Mathiowitz E, Laurencin CT. Method of making hydroxamic acid polymers from primary amide polymers. US Patent No. 5128420; 1992.
31. Panter S., Braughler J., and Hall E. Dextran-coupled deferoxamine improves outcome in a murine model of head injury. J Neurotrauma 9 1 (1992) 47-53
32. Fingleton B. MMPs as therapeutic targets - still a viable option?. Semin Cell Dev Biol 19 1 (2008) 61-68
33. Matsumura S.-I., Iwanaga S., Mochizuki S., Okamoto H., Ogawa S., and Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115 3 (2005) 599-609
34. Pyo R., Lee J., Shipley J.M., Curci J.A., Mao D., Ziporin S.J., et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105 11 (2000) 1641-1649
35. Goss K.J., Brown P.D., and Matrisian L.M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on the intestinal tumorigenesis. Int J Cancer 78 5 (1998) 629-635
36. Sang Q.X., Jin Y., Newcomer R.G., Monroe S.C., Fang X., Hurst D.R., et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 6 4 (2006) 289-316
37. Corbitt C.A., Lin J., and Lindsey M.L. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors?. Recent Patents Anticancer Drug Discov 2 2 (2007) 135-145
38. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol 17 (2001) 463-516